Sarepta Therapeutics, Inc. (SRPT)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
26.78+1.02 (+3.96%)
At close: 4:00 PM EDT
People also watch:
ACADCLDXCLVSICPTPTCT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open25.76
Prev Close25.76
Bid26.58 x 700
Ask27.25 x 200
Day's Range25.75 - 27.13
52wk Range8.00 - 41.97
1y Target EstN/A
Market Cap1.28B
P/E Ratio (ttm)-5.00
Beta1.76
Volume1,727,458
Avg Vol (3m)3,552,312
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • 3 Biotech Stocks With Explosive Upside Potential
    Motley Fool4 days ago

    3 Biotech Stocks With Explosive Upside Potential

    These three biotechs hold massive potential if everything goes according to plan.

  • optionMONSTER4 days ago

    What's behind put volume in Sarepta

    Sarepta Therapeutics has soared in recent months, but a large trader apparently believes that a big drop may be coming. optionMONSTER's market scanner detected the purchase of 6,500 September 8 puts in ...

  • Barrons.com17 days ago

    Sarepta Therapeutics: Patience Will Not Be Rewarded

    Shares of Sarepta Therapeutics (SRPT) are getting pounded today on speculation that it could have a harder time getting its Duchenne muscular dystrophy therapy approved. Leerink's Joseph Schwartz and Dae Gon Ha continue to argue that "patience may not be rewarded." They explain why: Since the FDA's seemingly simple request for additional dystrophin data, there has been very little news flow from Sarepta for longer than most on the street had expected. In an attempt to test the credence of the notion that "no news is good news," we analyzed historical drug delays that, not surprisingly, imply a strong binary move on the FDA's eventual decision.